Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Gastrotuss

PreclinicalSmall molecule

FFederico II University

Gastrotuss is one of 2 small molecule programs targeting Gastroesophageal Reflux. It is currently in Preclinical.

1

Indications

1

Total Trials

0

Active Trials

1

Competitors

Pipeline

Status by Indication[3][1]

Indication

Gastroesophageal RefluxUnknown status

Gastroesophageal RefluxPreclinical

Unknown status

Competition

Competitive Landscape

1 competitor in Gastroesophageal Reflux

#DrugCompanyPhaseTrials

UI059

KKorea United Pharm. Inc.

Gastrotuss

FFederico II University

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Gastroesophageal Reflux1 trial

Prospective, Comparative, Randomized, Controlled Trial on the Efficacy of the Treatment of Gastroesophageal Reflux Infant With Magnesium Alginate

Unknown status·FFederico II University·N/A·NCT01858584·75 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Gastrotuss. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Gastrotuss compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Gastrotuss. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Federico II University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: FFederico II University

Related News